cpi-818
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started May 3, 2019 (NCT03952078)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase ITK/TSKINHIBITOR
ITK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CCCN(C(=O)c2cc(Sc3cnc(NC(=O)C4CC4)s3)c(C)cc2OC)C[C@H]1C- Mol. weight
- 514.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5817577 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06730126 | Phase 2 | Dec 22, 2024 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT06561048 | Phase 3 | Oct 2, 2024 | Corvus Pharmaceuticals, Inc. |
| NCT06345404 | Phase 1 | Apr 30, 2024 | Corvus Pharmaceuticals, Inc. |
| NCT03952078 | Phase 1 | May 3, 2019 | Corvus Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1